{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:14:24Z","timestamp":1788563664770,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pneumonia"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pneumococcal disease (PD) is a leading cause of morbidity among US children, particularly those with chronic medical conditions (CMC) and immunocompromising conditions (IC), and the decline in PD incidence was less pronounced in the late pneumococcal conjugate vaccine (PCV) 13 period. This study quantified healthcare resource utilization (HCRU) and costs among commercially and Medicaid-insured children with PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational cohort study used Merative\u2122 MarketScan\u00ae Commercial Database and Multi-State Medicaid Databases to identify children with invasive pneumococcal disease (IPD), all-cause pneumonia (ACP), and acute otitis media (AOM) episodes using inpatient and outpatient claims. HCRU and costs per PD episode were assessed in the commercially and Medicaid-insured populations, stratified by age (&lt;2, 2-4, and 5-17 years) and risk group (CMC, IC, and no CMC\/IC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2018 and 2023, commercially insured children contributed 23.6 million person-years (PY) and Medicaid-insured children contributed 23.4 million PY; 423 and 664 children had IPD, 309,540 and 281,569 had ACP, and 2,721,354 and 2,596,201 had AOM in the commercial and Medicaid populations, respectively. In both databases, HCRU and cost was higher in children with CMC or IC, compared to no CMC\/IC across age groups for all PD manifestations. For IPD and ACP, inpatient admissions were 1.4 to 2.2-fold longer for children with CMC or IC. For IPD, costs per episode were 2-to-3-fold higher in children with CMC or IC, compared with those without CMC\/IC (Commercial: $76,278 and $72,130 vs. $22,371; Medicaid: $17,389 and $19,945 vs. $6,476, respectively). For ACP, costs were highest in children with IC, followed by CMC and no CMC\/IC (Commercial: $7,343, $2,637, and $809; Medicaid: $3,257, $1,160, and $356, respectively). AOM showed a similar pattern, with highest costs in children with IC (Commercial: $608; Medicaid: $178), followed by CMC ($442; $141), and lowest in those without CMC\/IC ($368; $123).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>US children with underlying conditions that increase susceptibility to PD experience substantially higher HCRU and costs compared with those without such conditions, across all PD manifestations, regardless of insurance type and age group. These findings underscore the need for risk-based prevention strategies, including vaccination, beyond early childhood in high-risk pediatric populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41479-026-00206-1","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:02:16Z","timestamp":1788562936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Healthcare resource utilization and cost of invasive pneumococcal disease, pneumonia, and acute otitis media in commercially and medicaid-insured children by risk group in the United States, 2018 to 2023"],"prefix":"10.1186","volume":"18","author":[{"given":"Salini","family":"Mohanty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolae","family":"Done","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Zion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayler","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsie","family":"Cassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Banniettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica P.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Feemster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"issue":"1","key":"206_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12916-018-1004-z","volume":"16","author":"D Thorrington","year":"2018","unstructured":"Thorrington D, Andrews N, Stowe J, Miller E, van Hoek AJ. Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control. BMC Med. 2018;16(1):13. https:\/\/doi.org\/10.1186\/s12916-018-1004-z.","journal-title":"BMC Med"},{"issue":"12 Suppl 2","key":"206_CR2","doi-asserted-by":"publisher","first-page":"S352","DOI":"10.1093\/infdis\/jiaa535","volume":"224","author":"GL Rodgers","year":"2021","unstructured":"Rodgers GL, Whitney CG, Klugman KP. Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe. J Infect Dis. 2021;224(12 Suppl 2):S352\u20139. https:\/\/doi.org\/10.1093\/infdis\/jiaa535.","journal-title":"J Infect Dis"},{"issue":"9","key":"206_CR3","first-page":"258","volume":"59","author":"C Centers for Disease","year":"2010","unstructured":"Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59(9):258\u201361. . https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20224542","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"25","key":"206_CR4","first-page":"521","volume":"62","author":"NM Bennett","year":"2013","unstructured":"Bennett NM, Pilishvili T, Whitney CG, Moore M, Gierke R, Harris AM. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6\u201318 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013;62(25):521\u20134.","journal-title":"MMWR"},{"issue":"34","key":"206_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.15585\/mmwr.mm6434a4","volume":"64","author":"M Kobayashi","year":"2015","unstructured":"Kobayashi M, Bennett NM, Gierke R, et al. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64(34):944\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm6434a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"37","key":"206_CR6","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","volume":"71","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(37):1174\u201381. https:\/\/doi.org\/10.15585\/mmwr.mm7137a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"206_CR7","unstructured":"CDC. Summary of risk-based pneumococcal vaccination recommendations. https:\/\/www.cdc.gov\/pneumococcal\/hcp\/vaccine-recommendations\/risk-indications.html"},{"issue":"1","key":"206_CR8","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1186\/s12889-022-14051-6","volume":"22","author":"T Hu","year":"2022","unstructured":"Hu T, Song Y, Done N, et al. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998\u20132018. BMC Public Health. 2022;22(1):1677. https:\/\/doi.org\/10.1186\/s12889-022-14051-6.","journal-title":"BMC Public Health"},{"issue":"11","key":"206_CR9","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1016\/j.vaccine.2024.03.013","volume":"42","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, Done N, Liu Q, et al. Incidence of pneumococcal disease in children =48 months old in the United States: 1998\u20132019<\/at. Vaccine. 2024;42(11):2758\u201369. https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.013.","journal-title":"Vaccine"},{"issue":"1","key":"206_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41479-023-00109-5","volume":"15","author":"T Hu","year":"2023","unstructured":"Hu T, Sarpong EM, Song Y, et al. Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis. Pneumonia (Nathan). 2023;15(1):8. https:\/\/doi.org\/10.1186\/s41479-023-00109-5. (In eng).","journal-title":"Pneumonia (Nathan)"},{"issue":"1","key":"206_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12879-022-07275-9","volume":"22","author":"T Hu","year":"2022","unstructured":"Hu T, Done N, Petigara T, et al. Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998\u20132018. BMC Infect Dis. 2022;22(1):294. https:\/\/doi.org\/10.1186\/s12879-022-07275-9.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"206_CR12","doi-asserted-by":"publisher","first-page":"18977","DOI":"10.1038\/s41598-020-75691-5","volume":"10","author":"A Lochen","year":"2020","unstructured":"Lochen A, Croucher NJ, Anderson RM. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci Rep. 2020;10(1):18977. https:\/\/doi.org\/10.1038\/s41598-020-75691-5.","journal-title":"Sci Rep"},{"key":"206_CR13","doi-asserted-by":"publisher","unstructured":"Yildirim I, Lapidot R, Shaik-Dasthagirisaheb YB, et al. Invasive pneumococcal disease after 2 decades of pneumococcal conjugate vaccine use. Pediatrics. 2024;153(1). https:\/\/doi.org\/10.1542\/peds.2023-063039.","DOI":"10.1542\/peds.2023-063039"},{"issue":"3","key":"206_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1542\/peds.2008-1702","volume":"125","author":"SL Kaplan","year":"2010","unstructured":"Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125(3):429\u201336. https:\/\/doi.org\/10.1542\/peds.2008-1702.","journal-title":"Pediatrics"},{"issue":"1","key":"206_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12913-023-09244-7","volume":"23","author":"T Hu","year":"2023","unstructured":"Hu T, Song Y, Done N, et al. Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014\u20132018. BMC Health Serv Res. 2023;23(1):398. https:\/\/doi.org\/10.1186\/s12913-023-09244-7.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"206_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/13696998.2025.2484919","volume":"28","author":"A Averin","year":"2025","unstructured":"Averin A, Weycker D, Lapidot R, et al. Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children. J Med Econ. 2025;28(1):517\u201323. https:\/\/doi.org\/10.1080\/13696998.2025.2484919. (In eng).","journal-title":"J Med Econ"},{"issue":"1","key":"206_CR17","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1186\/s12913-024-11898-w","volume":"24","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, Cossrow N, White M, et al. Burden of invasive pneumococcal disease, non-invasive all-cause pneumonia, and acute otitis media in hospitalized US children: a retrospective multi-center study from 2015 to 2020. BMC Health Serv Res. 2024;24(1):1574. https:\/\/doi.org\/10.1186\/s12913-024-11898-w. (In eng).","journal-title":"BMC Health Serv Res"},{"issue":"21","key":"206_CR18","doi-asserted-by":"publisher","first-page":"6751","DOI":"10.1182\/bloodadvances.2022009643","volume":"7","author":"TV Adamkiewicz","year":"2023","unstructured":"Adamkiewicz TV, Yee MEM, Thomas S, et al. Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines. Blood Adv. 2023;7(21):6751\u201361. https:\/\/doi.org\/10.1182\/bloodadvances.2022009643.","journal-title":"Blood Adv"},{"key":"206_CR19","doi-asserted-by":"publisher","unstructured":"Castro-Rodriguez JA, Abarca K, Forno E. Asthma and the risk of invasive pneumococcal disease: a meta-analysis. Pediatrics. 2020;145(1). https:\/\/doi.org\/10.1542\/peds.2019-1200.","DOI":"10.1542\/peds.2019-1200"},{"issue":"6","key":"206_CR20","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/INF.0000000000004730","volume":"44","author":"K Hamilton","year":"2025","unstructured":"Hamilton K, Luvsansharav UO, Xing W, et al. Characteristics of Invasive Pneumococcal Diseases Cases Among U.S. Children With Hematologic Malignancies Before and After Introduction of Thirteen-valent Pneumococcal Conjugate Vaccine, 2005\u20132019. Pediatr Infect Dis J. 2025;44(6):564\u201370. https:\/\/doi.org\/10.1097\/INF.0000000000004730.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"206_CR21","doi-asserted-by":"publisher","first-page":"e31467","DOI":"10.1002\/pbc.31467","volume":"72","author":"AB Payne","year":"2025","unstructured":"Payne AB, Gierke R, Xing W, et al. Prevention of Invasive Pneumococcal Disease Among Black or African American Children With and Without Sickle Cell Disease in the United States After Introduction of 13-Valent Pneumococcal Conjugate Vaccine, 2005 Through 2019. Pediatr Blood Cancer. 2025;72(3):e31467. https:\/\/doi.org\/10.1002\/pbc.31467.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"206_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/cid\/ciu348","volume":"59","author":"SI Pelton","year":"2014","unstructured":"Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis. 2014;59(5):615\u201323. https:\/\/doi.org\/10.1093\/cid\/ciu348.","journal-title":"Clin Infect Dis"},{"key":"206_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12913-016-1432-4","volume":"16","author":"D Weycker","year":"2016","unstructured":"Weycker D, Farkouh RA, Strutton DR, Edelsberg J, Shea KM, Pelton SI. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res. 2016;16:182. https:\/\/doi.org\/10.1186\/s12913-016-1432-4.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"206_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/ijcp.12234","volume":"68","author":"MA Rose","year":"2014","unstructured":"Rose MA, Christopoulou D, Myint TT, de Schutter I. The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe. Int J Clin Pract. 2014;68(1):8\u201319. https:\/\/doi.org\/10.1111\/ijcp.12234.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"206_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1542\/peds.2014-0473","volume":"134","author":"PY Iroh Tam","year":"2014","unstructured":"Iroh Tam PY, Madoff LC, Coombes B, Pelton SI. Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics. 2014;134(2):210\u20137. https:\/\/doi.org\/10.1542\/peds.2014-0473. (In eng).","journal-title":"Pediatrics"},{"key":"206_CR26","unstructured":"Merative. MarketScan research databases for life sciences researchers. https:\/\/www.merative.com\/content\/dam\/merative\/documents\/brief\/marketscan-research-databases-for-life-sciences-researchers.pdf"},{"key":"206_CR27","unstructured":"Merative MarketScan Research Databases. Commercial database & medicare database user guide - data year 2023. Merative. 2023."},{"issue":"2","key":"206_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40136-017-0151-7","volume":"5","author":"A Granath","year":"2017","unstructured":"Granath A. Recurrent Acute Otitis Media: What Are the Options for Treatment and Prevention? Curr Otorhinolaryngol Rep. 2017;5(2):93\u2013100. https:\/\/doi.org\/10.1007\/s40136-017-0151-7.","journal-title":"Curr Otorhinolaryngol Rep"},{"issue":"4","key":"206_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0030-6665(20)31103-8","volume":"24","author":"MV Goycoolea","year":"1991","unstructured":"Goycoolea MV, Hueb MM, Ruah C. Otitis media: the pathogenesis approach. Definitions and terminology. Otolaryngol Clin North Am. 1991;24(4):757\u201361. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1870869.","journal-title":"Otolaryngol Clin North Am"},{"issue":"3","key":"206_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1542\/peds.2014-2426","volume":"135","author":"I Yildirim","year":"2015","unstructured":"Yildirim I, Shea KM, Little BA, Silverio AL, Pelton SI. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease. Pediatrics. 2015;135(3):495\u2013503.","journal-title":"Pediatrics"},{"issue":"38","key":"206_CR31","doi-asserted-by":"publisher","first-page":"844","DOI":"10.15585\/mmwr.mm7338a3","volume":"73","author":"HA Hill","year":"2024","unstructured":"Hill HA, Yankey D, Elam-Evans LD, et al. Decline in Vaccination Coverage by Age 24 Months and Vaccination Inequities Among Children Born in 2020 and 2021 - National Immunization Survey-Child, United States, 2021\u20132023. MMWR Morb Mortal Wkly Rep. 2024;73(38):844\u201353. https:\/\/doi.org\/10.15585\/mmwr.mm7338a3.","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Pneumonia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-026-00206-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41479-026-00206-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-026-00206-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:02:17Z","timestamp":1788562937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41479-026-00206-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1186\/s41479-026-00206-1","relation":{},"ISSN":["2200-6133"],"issn-type":[{"value":"2200-6133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study involved de-identified, aggregate data from a pre-existing dataset that was licensed to Merck & Co., Inc., Rahway, NJ, USA, and was not subject to Institutional Review Board approval at Merck & Co., Inc., Rahway, NJ, USA or Analysis Group, Inc. Informed consent was not needed as all patients were anonymized and only aggregate data are reported here. A research review committee at Merck & Co., Inc., Rahway, NJ, USA approved the study protocol prior to the study initiation. All methods were performed in accordance with the relevant guidelines and regulations, including the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SM, MW, KC, YH, JW, KJ, NB and KF are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock\/stock options in Merck & Co., Inc., Rahway, NJ, USA.ND, YS, TW, ER, and TL are employees of Analysis Group, Inc., a consulting firm that received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA to conduct this study. AZ was employed by Analysis Group, Inc. during the conduct of this study.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"20"}}